Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2025-03-21 Regulatory Filings
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Isofol erhåller myndighetsgodkännande för att inleda klinisk studie med arfolitixorin
Regulatory Filings Classification · 98% confidence The document is a press release from Isofol Medical AB announcing that they have received regulatory approval (from BfArM in Germany) to commence a new clinical study for their drug candidate, arfolitixorin. It details the study's phase (Ib/II), purpose (treating metastatic colorectal cancer), location, and key personnel involved. This type of announcement, detailing clinical trial progress, regulatory milestones, and strategic updates, is characteristic of general corporate news releases aimed at investors. Since it is not a full financial report (10-K, IR), a specific financial event (CAP, DIV), or a formal regulatory filing like a proxy statement, it falls best under the general category for regulatory/corporate announcements that don't fit elsewhere, which is Regulatory Filings (RNS). Although it discusses clinical development, it is not a formal Audit Report (AR) or a dedicated Investor Presentation (IP). Given the context of a press release announcing a regulatory milestone, RNS is the most appropriate general classification.
2025-03-21 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'BOKSLUTSKOMMUNIKÉ 2024' (Year-End Report 2024) for Isofol Medical AB. It contains comprehensive financial information for the fourth quarter and the full year 2024, including income statements, key performance indicators (nyckeltal), and detailed management commentary on business operations, clinical trials, and future outlook. As it provides substantive financial data and analysis for a specific period, it is classified as an Interim/Quarterly Report. Q4 2024
2025-02-19 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ISOFOL MEDICAL AB (PUBL) YEAR-END REPORT 2024'. It contains comprehensive financial information for the fourth quarter and the full year 2024, including net revenue, results for the period, earnings per share, and cash equivalents. It also includes a detailed management discussion on clinical development, operational updates, and future outlook. Since it covers a period shorter than a full fiscal year (specifically the fourth quarter) and provides substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. Q4 2024
2025-02-19 English
Isofol appoints nomination committee ahead of the Annual General Meeting 2025
Board/Management Information Classification · 99% confidence The document explicitly discusses the appointment of members for the 'nomination committee for the Annual General Meeting 2025'. While it relates to the AGM, the core subject is the composition and process of the nomination committee, which is a governance function. The definitions provided include 'Governance Information (Code: CGR)' and 'AGM Information (Code: AGM-R)'. Since the document details the structure and members of a committee responsible for nominating directors/officers ahead of the AGM, it aligns most closely with Governance Information (CGR) regarding board structure and processes, rather than being the AGM presentation itself (AGM-R) or a general announcement about the meeting date. However, given the strong link to the upcoming AGM and the nomination process, it could also be argued as a specific pre-AGM governance announcement. Reviewing the options, CGR covers internal rules and board structure, which this directly impacts. If a more specific category existed for 'Nomination Committee Appointment', CGR is the best fit among the provided choices for governance structure updates.
2024-11-19 English
Isofol har utsett valberedningen inför årsstämman 2025
AGM Information Classification · 98% confidence The document is a press release announcing the appointment of the members of the Nomination Committee (Valberedningen) for the upcoming Annual General Meeting (AGM) in 2025. Key phrases include 'utsett valberedningen inför årsstämman 2025' (appointed the nomination committee for the AGM 2025) and details about shareholder representation and deadlines related to the AGM. This type of announcement, which concerns the preparation and governance structure leading up to the AGM, falls under the scope of AGM Information (AGM-R), as it directly relates to the procedures and participants of the Annual General Meeting.
2024-11-19 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Isofol Medical AB for the period January-September 2024. It contains detailed financial statements, key performance indicators (KPIs), management commentary on business trends, and clinical development updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2024
2024-11-12 Swedish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.